Block Lays Off Half Its Workforce, Over 4,000 Unemployed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy CRWD?
Source: CNBC
- Mass Layoff Impact: Block's announcement of a 50% workforce reduction, resulting in over 4,000 layoffs, reflects a pessimistic outlook on future economic conditions, which could negatively impact market confidence and stock performance.
- Industry Trend Warning: According to Challenger, Gray & Christmas, January 2026 saw the highest number of layoff announcements since 2009, indicating that companies are tightening their belts amid economic uncertainty, potentially signaling broader industry challenges ahead.
- Automation Driving Layoffs: CEO Jack Dorsey highlighted that automation driven by artificial intelligence is a contributing factor to the layoffs, predicting that many companies will undergo similar structural changes in the coming year, which may intensify job competition within the industry.
- Job Seeker Strategies: Experts recommend that laid-off employees actively negotiate for benefits like continued health insurance before leaving and broaden their job applications to adapt to the current sluggish hiring market, thereby increasing their chances of securing new employment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRWD
Wall Street analysts forecast CRWD stock price to rise
34 Analyst Rating
23 Buy
11 Hold
0 Sell
Moderate Buy
Current: 390.410
Low
353.00
Averages
559.71
High
640.00
Current: 390.410
Low
353.00
Averages
559.71
High
640.00
About CRWD
CrowdStrike Holdings, Inc. is a global cybersecurity company that provides cloud-delivered protection of endpoints, cloud workloads, identity and data. Its Falcon platform is designed for cybersecurity consolidation, purpose-built to stop breaches. The platforms collect and integrate data from across the enterprise, including endpoints, cloud workloads, identities, and third-party sources. It offers 29 cloud modules on its Falcon platform via a software as a service (SaaS) subscription-based model that spans multiple large markets, including corporate endpoint and cloud workload security, managed security services, security and vulnerability management, information technology (IT) operations management, identity protection, next-generation security information and event management (SIEM) and log management, threat intelligence services, data protection, SaaS security posture management, automation and response (SOAR) and artificial intelligence powered workflow automation, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Receives FDA Approval for New Drug Foundayo
- New Drug Approval: Eli Lilly announced that its once-daily GLP-1 drug Foundayo has received FDA approval and is set to launch on April 6 via the LillyDirect online platform, addressing strong market demand for weight loss medications and further solidifying its position in the obesity treatment market.
- Positive Market Outlook: Analysts forecast Foundayo to generate approximately $1.55 billion in sales this year, with projections growing to about $14.8 billion by 2030, indicating the drug's significant potential in the future market and its capacity to reshape obesity treatment paradigms.
- Significant Competitive Advantage: Compared to rival Novo Nordisk's Wegovy, Foundayo offers greater flexibility in dosing and dietary restrictions, and has demonstrated superior efficacy in clinical studies for diabetes patients, which may attract a broader patient base to choose this medication.
- Accelerated Strategic Transformation: Eli Lilly built up a substantial stockpile of the drug ahead of FDA approval to ensure a swift market response, showcasing the company's foresight and execution in its new drug launch strategy, thereby enhancing its competitiveness in the biopharmaceutical industry.
See More
CrowdStrike Rated Buy with $500 Target by Benchmark
- Rating Upgrade: Benchmark initiated coverage on CrowdStrike with a Buy rating and a $500 price target, highlighting the company's technological leadership and high AI defensibility in the cybersecurity sector, with a total addressable market of approximately $150 billion.
- Growth Potential: Analysts project that CrowdStrike's annual recurring revenue (ARR) will nearly double from $5.25 billion in FY2026 to $10 billion by FY2031, showcasing strong growth prospects in cloud security and next-gen identity management.
- Profitability Fundamentals: CrowdStrike maintains solid profitable growth fundamentals targeting a Rule of 50+, with a history of consistent beat-and-raise execution, indicating a competitive edge and sustainable growth trajectory in the market.
- Technical Analysis Support: Analysts noted that CrowdStrike's stock shows trading support for a positive reversal in technical analysis, further boosting investor confidence in its future performance.
See More
Investment Opportunity Analysis for Nasdaq-100 Index
- Historical Return Potential: The Nasdaq-100 has achieved an average five-year return of 103% over the past two decades, with historical data suggesting that it could nearly double investors' money in the next five years, making it an attractive option for investors.
- AI-Driven Growth: The Invesco QQQ Trust is heavily invested in AI-related stocks, with top holdings including tech giants like Nvidia and Apple, which are expected to benefit from the rapid development of AI technologies, further enhancing market performance.
- Market Correction Timing: The Nasdaq Composite is currently in a market correction, down over 10% from its all-time high, and historical data indicates that such corrections have led to an average five-year return of 146%, presenting a favorable investment opportunity.
- Concentration Risk Warning: While the Invesco QQQ Trust has a reasonable expense ratio of 0.18%, its top ten holdings account for nearly 50% of its performance, prompting investors to carefully consider the concentration risk and potential price volatility.
See More
Nasdaq-100 Expected to Perform Well in Future
- Historical Returns: The Nasdaq-100 has achieved a 103% average five-year total return over the past two decades, indicating that investors could potentially double their money in the next five years, thus drawing increased investor interest.
- Market Correction Opportunity: The Nasdaq Composite fell into correction territory last month, which historically has been viewed as a good time to invest; after 13 market corrections, the Nasdaq-100's five-year total returns averaged 146%, suggesting a favorable outlook.
- AI-Driven Growth: The Invesco QQQ Trust is heavily invested in AI-related stocks, with over 80% of its assets concentrated in technology and consumer discretionary sectors, which are expected to perform well due to the rise of artificial intelligence, enhancing its investment appeal.
- Reasonable Expense Ratio: The Invesco QQQ Trust has an expense ratio of 0.18%, meaning shareholders pay $18 annually for every $10,000 invested; despite concentration risks, the current buying opportunity remains attractive for long-term investors.
See More
Market Rises on Optimism Over Iran War Resolution
- Market Optimism: The stock market rose on Tuesday as President Trump expressed willingness to end the Iran War without reopening the Strait of Hormuz, which Jim Cramer noted presents various opportunities, potentially leading to lower oil prices that could alleviate inflation concerns and facilitate interest rate cuts by the Federal Reserve later this year.
- AI Partnership: Nvidia announced a strategic partnership with custom chipmaker Marvell Technology, which is boosting overall sentiment in the artificial intelligence sector, indicating a growing confidence in AI-related investments.
- Cybersecurity Challenges: CEO Nikesh Arora of Palo Alto Networks is on a
See More
Analysts Bullish on Arm and CrowdStrike's Future Prospects
- Arm's New Chip Strategy: Arm Holdings has launched the new Arm AGI CPU chip, projecting annual revenue of $15 billion by 2031, which will elevate total revenue to $25 billion, indicating strong growth potential in the AI data center market.
- Analyst Rating Upgrade: Needham upgraded Arm's stock to a buy with a price target of $200 per share, representing a 45% upside from the current price of $138, reflecting confidence in its new strategic direction.
- CrowdStrike's Growth Potential: Morgan Stanley upgraded CrowdStrike's rating to buy and raised the price target to $510, anticipating 20% annual revenue growth over the next few years, showcasing its strong performance in the cybersecurity sector.
- Platform Innovation Drive: CrowdStrike's Falcon Flex platform saw a 120% increase in annual recurring revenue, while the launch of the Charlotte AI AgentWorks ecosystem enhances customers' ability to customize security agents, further solidifying its market position.
See More
Eli Lilly Receives FDA Approval for New Drug Foundayo
- New Drug Approval: Eli Lilly announced that its once-daily GLP-1 drug Foundayo has received FDA approval and is set to launch on April 6 via the LillyDirect online platform, addressing strong market demand for weight loss medications and further solidifying its position in the obesity treatment market.
- Positive Market Outlook: Analysts forecast Foundayo to generate approximately $1.55 billion in sales this year, with projections growing to about $14.8 billion by 2030, indicating the drug's significant potential in the future market and its capacity to reshape obesity treatment paradigms.
- Significant Competitive Advantage: Compared to rival Novo Nordisk's Wegovy, Foundayo offers greater flexibility in dosing and dietary restrictions, and has demonstrated superior efficacy in clinical studies for diabetes patients, which may attract a broader patient base to choose this medication.
- Accelerated Strategic Transformation: Eli Lilly built up a substantial stockpile of the drug ahead of FDA approval to ensure a swift market response, showcasing the company's foresight and execution in its new drug launch strategy, thereby enhancing its competitiveness in the biopharmaceutical industry.
See More
CrowdStrike Rated Buy with $500 Target by Benchmark
- Rating Upgrade: Benchmark initiated coverage on CrowdStrike with a Buy rating and a $500 price target, highlighting the company's technological leadership and high AI defensibility in the cybersecurity sector, with a total addressable market of approximately $150 billion.
- Growth Potential: Analysts project that CrowdStrike's annual recurring revenue (ARR) will nearly double from $5.25 billion in FY2026 to $10 billion by FY2031, showcasing strong growth prospects in cloud security and next-gen identity management.
- Profitability Fundamentals: CrowdStrike maintains solid profitable growth fundamentals targeting a Rule of 50+, with a history of consistent beat-and-raise execution, indicating a competitive edge and sustainable growth trajectory in the market.
- Technical Analysis Support: Analysts noted that CrowdStrike's stock shows trading support for a positive reversal in technical analysis, further boosting investor confidence in its future performance.
See More
Investment Opportunity Analysis for Nasdaq-100 Index
- Historical Return Potential: The Nasdaq-100 has achieved an average five-year return of 103% over the past two decades, with historical data suggesting that it could nearly double investors' money in the next five years, making it an attractive option for investors.
- AI-Driven Growth: The Invesco QQQ Trust is heavily invested in AI-related stocks, with top holdings including tech giants like Nvidia and Apple, which are expected to benefit from the rapid development of AI technologies, further enhancing market performance.
- Market Correction Timing: The Nasdaq Composite is currently in a market correction, down over 10% from its all-time high, and historical data indicates that such corrections have led to an average five-year return of 146%, presenting a favorable investment opportunity.
- Concentration Risk Warning: While the Invesco QQQ Trust has a reasonable expense ratio of 0.18%, its top ten holdings account for nearly 50% of its performance, prompting investors to carefully consider the concentration risk and potential price volatility.
See More
Nasdaq-100 Expected to Perform Well in Future
- Historical Returns: The Nasdaq-100 has achieved a 103% average five-year total return over the past two decades, indicating that investors could potentially double their money in the next five years, thus drawing increased investor interest.
- Market Correction Opportunity: The Nasdaq Composite fell into correction territory last month, which historically has been viewed as a good time to invest; after 13 market corrections, the Nasdaq-100's five-year total returns averaged 146%, suggesting a favorable outlook.
- AI-Driven Growth: The Invesco QQQ Trust is heavily invested in AI-related stocks, with over 80% of its assets concentrated in technology and consumer discretionary sectors, which are expected to perform well due to the rise of artificial intelligence, enhancing its investment appeal.
- Reasonable Expense Ratio: The Invesco QQQ Trust has an expense ratio of 0.18%, meaning shareholders pay $18 annually for every $10,000 invested; despite concentration risks, the current buying opportunity remains attractive for long-term investors.
See More
Market Rises on Optimism Over Iran War Resolution
- Market Optimism: The stock market rose on Tuesday as President Trump expressed willingness to end the Iran War without reopening the Strait of Hormuz, which Jim Cramer noted presents various opportunities, potentially leading to lower oil prices that could alleviate inflation concerns and facilitate interest rate cuts by the Federal Reserve later this year.
- AI Partnership: Nvidia announced a strategic partnership with custom chipmaker Marvell Technology, which is boosting overall sentiment in the artificial intelligence sector, indicating a growing confidence in AI-related investments.
- Cybersecurity Challenges: CEO Nikesh Arora of Palo Alto Networks is on a
See More
Analysts Bullish on Arm and CrowdStrike's Future Prospects
- Arm's New Chip Strategy: Arm Holdings has launched the new Arm AGI CPU chip, projecting annual revenue of $15 billion by 2031, which will elevate total revenue to $25 billion, indicating strong growth potential in the AI data center market.
- Analyst Rating Upgrade: Needham upgraded Arm's stock to a buy with a price target of $200 per share, representing a 45% upside from the current price of $138, reflecting confidence in its new strategic direction.
- CrowdStrike's Growth Potential: Morgan Stanley upgraded CrowdStrike's rating to buy and raised the price target to $510, anticipating 20% annual revenue growth over the next few years, showcasing its strong performance in the cybersecurity sector.
- Platform Innovation Drive: CrowdStrike's Falcon Flex platform saw a 120% increase in annual recurring revenue, while the launch of the Charlotte AI AgentWorks ecosystem enhances customers' ability to customize security agents, further solidifying its market position.
See More
